海正药业：子公司获得芬苯达唑内服混悬液兽药批准文号

Core Viewpoint - Zhejiang Hai Zheng Animal Health Products Co., Ltd., a subsidiary of Hai Zheng Pharmaceutical (600267), has received approval from the Ministry of Agriculture and Rural Affairs for its fenbendazole oral suspension veterinary drug, which will enhance the company's product line and market competitiveness in the veterinary medicine sector [1] Group 1 - The approved product is classified as a Category V new veterinary drug, effective from April 25, 2025, to April 24, 2030 [1] - The drug is intended for the treatment of infections caused by pig roundworms, esophageal worms, and whipworms [1] - The application for the approval was submitted on January 11, 2025, indicating a proactive approach by the company in expanding its veterinary product offerings [1]